Update on current business operations of the Company.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ishita Drugs informed stock exchanges that its Board met on June 13, 2025 to review business operations. The company is upgrading its manufacturing facility at Sanand, Ahmedabad to comply with the Revised Schedule M under the Drug Rules, 1945. Consultants have been appointed for the upgrade, the design and layout have been finalized and approved by the relevant regulatory authority, and implementation work has already begun. The company has also applied to the government for an extension in the timeline to complete the Revised Schedule M compliance.
This is a routine regulatory-compliance update with no immediate financial impact. Shareholders should note that compliance upgrade costs and any production disruptions during the transition could affect near-term margins, but no orders, contracts, or revenue guidance have been disclosed.